Business Wire

Loop Energy Records Over 75,000 Kilometers of Operation for Fuel Cell Municipal Bus Fleet in Nanjing, China

28.6.2021 15:00:00 EEST | Business Wire | Press release

Share

Ahead of the company’s upcoming Investor Day, Loop Energy (TSX: LPEN), a developer and manufacturer of hydrogen fuel cell-based solutions, reports that the pilot transit bus fleet of Skywell New Energy Vehicles Group (Skywell) in Nanjing, China has now been fully operational for 45 days and has already accumulated 75,000 kilometers of in-service operations. Loop’s company management will share additional details about the fleet deployment and other business achievements for the Company during its Investor Day on Tuesday, June 29 at 10:00 a.m. PDT (1:00 p.m. EDT).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210628005227/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Loop Energy records over 75,000 kilometers of operation for fuel cell municipal bus fleet of Skywell New Energy Vehicles Group in Nanjing, China (Photo: Business Wire)

Loop Energy announced in April the fulfillment of a ten-unit order of the company’s proprietary eFlow® fuel cell modules from Beijing IN-Power for integration by Skywell. This marked the second phase milestone of a memorandum of understanding between the Lishui Economic Development Zone of Nanjing and Beijing IN-Power—Loop Energy’s China-based joint venture partner supplying the fuel cell engines.

“As we progress toward large-scale commercial deployment of hydrogen fuel cell vehicles in China, these impressive operational results demonstrate Skywell’s expertise, Loop’s product maturity, and the market’s accelerating adoption of hydrogen fuel cell technology,” said Ben Nyland, President and Chief Executive Officer of Loop Energy. “We are very pleased to see the strong results of our eFlow technology on the road, which continues to validate Loop’s unique value proposition of greater fuel efficiency, higher power, and extended range.”

“This pilot fleet deployment has gone exceptionally well and is setting the stage for continued success between Loop Energy and IN-Power as we continue to collaborate with Skywell to advance the fuel cell market in China,” said John Zhang, Founder and President of IN-Power.

“The Loop fuel cell systems are performing very well, and we are impressed with the quality of the product,” said Ms. Zou Ran (Joanna), Director of External Affairs & Brand of Skywell New Energy Vehicles Group. “The support of the IN-Power and Loop teams has been critical in achieving the rapid deployment of this pilot fleet and represents a major step towards reaching the objective of implementing similar fuel cell solutions across a wide range of our specialty and commercial vehicles.”

“We are extremely pleased with the successful operation of these zero-emission hydrogen electric buses,” said Mr. Cuichangong, Deputy Secretary of Party Work Committee of the Lishui Economic Development Zone. “This is another meaningful step in establishing the Lishui Economic Development Zone of Nanjing as a fuel cell and hydrogen centre of excellence in China and reaffirms our commitment to providing safe, reliable, energy-efficient transportation throughout the district.”

To learn more about the Skywell fleet deployment and performance, register to attend Loop Energy’s Investor Day video conference call at investors.loopenergy.com.

About Beijing IN-Power Electric Co., Ltd.

Founded in 2004, Beijing IN-Power is a high-tech Sino-foreign joint venture enterprise, headquartered in the High-tech Industrial Park, Zhongguancun, of Beijing. Through IN-Power’s two R&D Centers, and four wholly-owned subsidiaries and twenty-five offices all over China, the company is engaged in the development, manufacturing and integration of new energy and power electronics technology, equipment and engineering services. For more information, please visit http://en.in-power.net/.

About Skywell New Energy Vehicles Corp.

Skywell New Energy Vehicles Corp., formed in 2011 following the acquisition of Nanjing Jinlong Bus Manufacturing Co., is a leading developer and global supplier of electric vehicles. With headquarters located in the Lishui Airport Economic Development Zone in Nanjing, China, with production factories located in Wuhan, Shenzhen and Xianyang, Skywell manufactures and markets an extensive range of sustainable vehicles from light-duty automobiles, to medium and heavy-duty buses, commercial and specialty fleet trucks. The company also operates buses in the Lishui district of China. www.skywellcorp.com

About Loop Energy Inc.

Loop Energy is a leading designer and manufacturer of fuel cell systems targeted for the electrification of commercial vehicles, including, light commercial vehicles, transit buses and medium and heavy-duty trucks. Loop’s products feature the Company’s proprietary eFlow™ technology in the fuel cell stack’s bipolar plates. eFlow™ was designed to enable commercial customers to achieve performance maximization and cost minimization. Loop works with OEMs and major vehicle sub-system suppliers to enable the production of hydrogen fuel cell electric vehicles. For more information about how Loop is driving towards a zero-emissions future, visit www.loopenergy.com.

This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflect management’s current expectations regarding future events. Forward‐looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the ability of the Company to execute on its strategy and the factors discussed under “Risk Factors” in the final long-form prospectus of the Company dated February 18, 2021. Loop disclaims any obligation to update these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Loop Energy Media Contact: Ashley Eisner | Tel: +1.212.697.2600 | aeisner@gscommunications.com
Loop Energy Business Contact: George Rubin | Tel: +1.604.828.8185 | grubin@loopenergy.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye